Trials / Completed
CompletedNCT00749775
Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Eplerenone Observational Study Of Safety And Efficacy Evaluation To Normalize Blood Pressure For Clinical Effectiveness
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,338 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To collect the efficacy and safety information of Eplerenone on patients with hypertension related to their appropriate use in daily practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selara | Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food. |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2008-09-09
- Last updated
- 2020-12-22
- Results posted
- 2014-01-08
Source: ClinicalTrials.gov record NCT00749775. Inclusion in this directory is not an endorsement.